---
schema_version: "secwatch.filing_event.v1"
accession: "0000950142-22-000983"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2022-03-09T23:59:59+00:00"
generated_at: "2026-06-27T00:27:42.463250+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NRx CEO Javitt retires; Robert Besthof named interim CEO; narrows focus to US

## Summary
- Dr. Jonathan Javitt retired as CEO effective March 8, 2022; becomes Chief Scientist and remains on Board.
- Robert Besthof, Head of Operations, appointed Interim CEO; received 100,000 stock options at $2.61/share.
- Javitt consulting agreement: $250,000 upfront plus $75,000/month for one year.
- Company narrows geographic focus to US; ceasing efforts in Georgia and Caucasus due to geopolitical environment.
- Continues development of ZYESAMI for Critical COVID-19 and psychiatric pipeline including NRX-101.

## SEC filing metadata
- accession: 0000950142-22-000983
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2022-03-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000095014222000983/0000950142-22-000983-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000095014222000983/eh220233089_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950142-22-000983
- JSON: https://secwatch.observer/filing/0000950142-22-000983.json
- Plain text: https://secwatch.observer/filing/0000950142-22-000983.txt

## Key facts
- Executive change
  Jonathan Javitt retired as Chief Scientist at NRX Pharmaceuticals, Inc..
  - Action: retired
  - Role: Chief Scientist
  source text: On March 8, 2022, Dr. Jonathan Javitt, MD, MPH, announced his retirement from his position as Chief Executive Officer of NRx Pharmaceuticals, Inc. (the “ Company ”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000095014222000983/0000950142-22-000983-index.htm
- Executive change
  Robert Besthof was appointed as Interim Chief Executive Officer at NRX Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Interim Chief Executive Officer
  source text: On March 8, 2022, the Board appointed Mr. Robert Besthof to serve as Interim Chief Executive Officer of the Company during the transition.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000095014222000983/0000950142-22-000983-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.